首页|Comparative Evaluation of Antitumor Chinese Patent Medicine Injections Based on Evidence-Based Medicine and Markov Model

Comparative Evaluation of Antitumor Chinese Patent Medicine Injections Based on Evidence-Based Medicine and Markov Model

扫码查看
Objective:The objective of this study was to explore the safety,efficacy,economy,and other aspects of frequently-used antitumor Chinese patent medicine injections through a comprehensive evaluation of evidence-based medical research to provide scientific information and decision-making basis for drug selection,rational drug use,public awareness of safe drug use,and medical insurance.Materials and Methods:The names of five frequently used antitumor Chinese patent medicine injections were used as search terms,including the compound Sophora flavescens injection,Kangai injection,Aidi injection,Kanglaite injection,and Brucea javanica oil emulsion injection.Relevant evidence-based medical research was extracted from the databases.A descriptive evaluation was conducted,and the Markov model was used for the cost-benefit analysis.Finally,the above injections are ranked by comprehensive scores using the multi-criteria decision analysis and Delphi method.Results:The five injections had their own advantages in enhancing the effectiveness of anti-tumor treatments,improving the quality of life for cancer patients,and reducing the incidence of adverse reactions.From the perspective of economy and other attributes,compound S.flavescens was superior to B.javanica oil,Aidi,Kangai,and Kanglaite.After a comprehensive evaluation of the above five injections,the compound S.flavescens injection received the highest score.Conclusions:Compound S.flavescens,Kangai,Aidi,B.javanica oil,and Kanglaite have their own advantages in effectiveness and no significant difference in safety.Compound S.flavescens injection has the highest comprehensive score.Clinical attention should be paid to monitoring the initial stage of medication and special groups.

Anti-tumor Chinese patent medicinecomprehensive evaluationmedication safetypharmacoeconomicsrational drug use

Jing Yang、Yan-Peng Wang、Wen-Gong Yu、Yu-Yao Guan、Prince Emmanuel Opoku Amponsah、Xian-Shuai Tang、Ying-Zi Sun、Lei Zheng

展开 >

School of Medicine and Pharmacy,Ocean University of China,Qingdao,China

Department of Pharmacy,Shandong Medical College,Jinan,China

Department of Pharmacy,Cheeloo College of Medicine,Shandong Provincial Third Hospital,Shandong University,Jinan,China

Biomedical Engineering Graduate School,University of Arizona,Tucson,AZ,USA

展开 >

special fund project for clinical research for the Shandong Province Medical and Health Technology Development Plan ProjectShandong Natural Science Foundation General ProjectShandong TCM Science and Technology ProjectClinical Medical Technology Innovation Plan of Jinan Science and Technology Bureau2021 Shandong Medical Association Clinical Research Fund-Qilu Special ProjectShandong Province Medical and Health Technology Development PlanShandong Natural Science Foundation General Project

202009021072ZR2023MG0642021-M199202134016YXH2022ZX02050202213010928ZR2022MH250

2024

世界中医药杂志(英文版)
世界中医药学会联合会

世界中医药杂志(英文版)

CSTPCD
ISSN:2311-8571
年,卷(期):2024.10(2)